KLRK1 and urinary bladder carcinoma: Moreover, co-treatment with R8-liposome BCG-CWS and BCG mediated surface specific ligands (NKG2D) in bladder cancer cells; this effect resulted in enhanced sensitivity to cytolysis by lymphokine-activated killing cells [39].